Bethesda, MD – November 7, 2018 – Precision Xtract, part of Precision Value & Health, today announced Zac Stillerman, acclaimed healthcare industry operator and strategist, as new president and general manager. Responsible for leading Precision Xtract through its next phase of growth, Stillerman has a proven ability to translate vision and strategy into dynamic collaboration and first-class execution. He joins Precision Xtract at a time of growing demand from innovative life sciences companies for essential consulting activities, including health economic outcomes research, value demonstration, pricing and market access, and commercialization.

Stillerman comes to Precision Xtract from the Advisory Board Company, a best practices firm that uses a combination of research, technology, and consulting to improve the performance of healthcare organizations around the world. While at Advisory Board, Stillerman served as chief operating officer of its market-leading consulting services group, which generated more than $130 million in annual revenues. Prior to that role, he co-led Advisory Board’s new product development group and launched several analytics-based, innovative product lines that delivered optimized performance and commercialization support for healthcare organizations during his tenure. Stillerman’s extensive knowledge base includes mastery of core system optimization, clinical operations, value-based care, physician practice management, financial reporting, and revenue cycle.

Discussing Stillerman’s unique experience and qualifications, Precision Medicine Group CEO Mark Clein commented, “Zac’s reputation, background, and drive make him uniquely positioned to spur innovation while ensuring that our global pharma, biotech, and device clients will continue to receive the highest level of guidance and scalable support.”

As part of his responsibilities at the helm of Precision Xtract, Stillerman will also lead Precision Health Economics which is well known in the market for its high-level, rigorous health policy research and consultation, including novel approaches to quantifying the value of innovative therapies and expert ICER review navigation.

Expressing his enthusiasm for the opportunity, Stillerman explains, “I am excited to be joining Precision Xtract as president at this important time. Helping pharmaceutical and biotech companies get therapies in the hands of patients who need them most is a passion of mine, and I look forward to working with all of my Precision colleagues to support our clients in this critical effort.”


About Precision Xtract
Precision Xtract, the health economics, market access, and payer analytics consulting arm of Precision Value & Health, is comprised of top-tier talent including scientists, former payer and pharma executives, and world-respected academicians ready to partner with clients throughout the United States, Europe, and beyond. With over 140 employees in 7 offices worldwide, Precision Xtract’s breadth and depth of expertise complements an integrated, interdisciplinary approach to informing and guiding pharma, biotech, and device clients to commercial success.


About Precision Health Economics
Precision Health Economics (PHE), a Precision Value & Health company, combines the scientific expertise of academic researchers with the practical insights of a professional consulting firm. As a leader in advancing evidence-based health policy, PHE produces highly impactful research on the economic and social value of innovative treatments and care delivery to reach payers, healthcare providers, policymakers, patients, and other key stakeholders. PHE’s work has been published extensively in leading outlets such as Health Affairs, JAMA, and the American Journal of Managed Care.

To learn more about PHE, please visit

# # #

Media Contact:
Louis Landon, Precision Medicine Group Media Relations